Inventiva S.A. (IVA)
After hours:
| Previous Close | 3.9000 |
| Open | 3.9800 |
| Bid | 0.0000 x 900 |
| Ask | 0.0000 x 900 |
| Day's Range | 3.8500 - 4.0300 |
| 52 Week Range | 3.7500 - 15.7800 |
| Volume | |
| Avg. Volume | 7,031 |
| Market Cap | 193.01M |
| Beta (5Y Monthly) | 1.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3330 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Inventiva reports its 2022 first-half financial results and provides a corporate update
Cash position1 at €87.2 million as of June 30, 2022, compared to €95.4 million as of December 31, 2021 Receipt of a €4 million milestone payment from Inventiva’s partner AbbVie for cedirogant Phase IIb clinical trial initiation accounted for in 2021 revenues and H1 2022 cash flowInventiva entered into a credit facility for up to €50 million, subject to conditions, and a related warrant agreement with the European Investment Bank (EIB)2Inventiva raised approximately €14.7 million through a combin
- GlobeNewswire
Inventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China
Sino Biopharm a leading Chinese pharmaceutical group, through CTTQ will oversee the development and commercialization of lanifibranor in Greater ChinaLanifibranor is an orally-available small molecule with breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) following a positive Phase IIb trial in patients with non-alcoholic steatohepatitis (NASH). Lanifibranor is currently evaluated in a pivotal Phase III trial in NASHInventiva will receive a $12 million upfront, $5
- Zacks
Here's Why Inventiva S.A. Sponsored ADR (IVA) is Poised for a Turnaround After Losing 18.4% in 4 Weeks
Inventiva S.A. Sponsored ADR (IVA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
